Tag: Novartis

2019 Monica Warner Award: Call for Nominations

Novartis has announced that nominations are open for the 10th Annual Monica Warner Award, which commemorates the life and work of Monica Warner as a driving force in the neuroendocrine tumor (NET) community. Nominations will be accepted until December…

9th Annual Monica Warner Award: Call for Nominations

Novartis has announced that nominations are open for the 9th Annual Monica Warner Award, which commemorates the life and work of Monica Warner as a driving force in the neuroendocrine tumor (NET) community. Nominations will be accepted until December…

Call for Nominations: 7th Annual Warner Advocacy Award

Novartis Oncology and The NET Alliance have announced that nominations are open for the 7th Annual Warner Advocacy Award. This annual award was established by Novartis in 2009 in honor of Monica Warner, who passed away in August 2009, to recognize the …

10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community

As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

• PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society

9 News Items for the Carcinoid and Neuroendocrine Cancer Community

1. Groundbreaking research from Novartis as they develop drugs that train our immune system to detect and fight tumors. Dr. Glenn Dranoff, a cancer vaccine expert, will lead Novartis’ new research efforts in the area of immuno-oncology. Read …

10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

Novartis Offers New Sandostatin LAR Depot Co-Pay Assistance Program

A new co-pay assistance program for carcinoid syndrome patients taking Sandostatin® LAR Depot has been established by Novartis Pharmaceuticals Corporation, effective February 2014.

With the Sandostatin® LAR Depot Co-Pay Assistance Program, eligible…

First Ever Global Survey for Carcinoid & Neuroendocrine Tumor (NET) Patients

Participate in the first ever global survey specifically focused on NET (neuroendocrine tumor) cancer!

Please help the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation – both members of the International Neuroendocrine Cancer…

New Jersey Carcinoid Cancer NETwork Conference Videos Now Available

Carcinoid and neuroendocrine tumor (NET) patients, physicians, caregivers, support group leaders and patient advocates gathered to learn more from nationally and internationally recognized carcinoid/NET specialists and local physician specialists…